Refine by
Antigen Targeting Technology
8 companies found
Technologybased inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to ...
Technologybased inDallas, TEXAS (USA)
Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with operations in the United States, Latin America, Europe and Asia, the company’s proprietary technology ...
Technologybased inCambridge, UNITED KINGDOM
Based in Cambridge, one of Europe's largest bioscience hubs, Biorbyt has a simple yet challenging mission: to provide the best service to the global scientific community. We achieve this by collaborating with the world’s finest researchers and ...
Plasma cells are specialised B lymphocytes that secrete antibodies (glycoproteins) in response to infection by antigens (toxins or foreign substances). Antibodies, also known as immunoglobulins (Ig), usually have a high affinity to a specific ...
Technologybased inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
in a single, transferable, conditionally active design. Right Place at the Right Time. With PROgrammed Tumor Engagement & Checkpoint/Co-stimulation Targeting, the ProTECT platform delivers multifunctional tumor-specific activity while ...
Technologybased inNew Orleans, LOUISIANA (USA)
Our mission is to advance infectious disease diagnosis and improve patient care using novel diagnostic platforms that produces rapid and accurate results from patient samples. Our versatile platforms address critical needs for current infectious ...
To address these issues, NanoPin uses an antibody enrichment approach to capture species-specific biomarker peptides released upon trypsin digestion of the serum of infected individuals and employs mass spectrometry to identify these peptides with ...
Technologybased inReno, NEVADA (USA)
DxDiscovery is a biotechnology Research & Development firm. The corporate goal is to develop quality, high-affinity antibodies to microbial antigens. These antibodies are incorporated into rapid POC diagnostics, or they may be developed as ...
An essential aspect of immunoassay development is the identification of target antigens that are shed or secreted during infection that can be used as targets for diagnosis. In an attempt to ...
Technologybased inVienna, AUSTRIA
Hookipa Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system. We are using our non-replicating and ...
The immune system is the body’s natural defense mechanism against pathogens. Our proprietary technology is capable of targeting and treating disease with a tailored immune response. Our science is based on a novel and highly differentiated ...
Technologybased inCarlton South, AUSTRALIA
Chimeric Therapeutics is a clinical stage cell therapy company focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease ...
CHM 2101 (CDH17 CAR T) is an optimized 3rd generation CAR T cell therapy that is the first to target ...